Shared Multi-Omic Data for Advancing Neuroendocrine Neoplasm Research

NETRF-funded researchers have recently reported in the journal GigaScience the first multi-omic dataset of patient-derived tumor organoids of neuroendocrine neoplasms (NENs). This includes large cell neuroendocrine carcinomas, lung neuroendocrine tumors, and small intestinal NETs. This study is a testament to the power of collaboration, including NETRF-funded researchers across the globe: Nicolas Alcala, PhD, Lynnette Fernandez-Cuesta, PhD, Matthieu Foll, PhD, Talya Dayton, PhD, and Hans Clevers, MD, PhD. The dataset offers a comprehensive resource for the research community, which may expedite the search for new neuroendocrine cancer treatments and cures.

Dr. Hans Clevers, MD, PhD of the Hubrecht Institute in the Netherlands, was awarded a 2017 NETRF Petersen Accelerator Award to develop tumor models such as patient-derived tumor organoids (PDTOs). Tumor organoids are three-dimensional experimental models that allow scientists to study tumor growth and test therapies. This team established one of the first PDTO biobanks specifically for NENs. This biobank includes organoids from both NETs, categorized by grade and NECs. The creation of this biobank represents a significant step forward in our ability to study these rare cancers, providing a critical tool for modeling disease progression and testing personalized treatments.

The multi-omic dataset associated with this biobank, encompassing whole-genome and RNA sequencing of organoids from the lung, small intestine, and pancreas, along with matched primary or metastatic tumor samples, offers a comprehensive resource for the research community. This dataset also includes longitudinal sampling, quality controls, molecular analysis scripts, and histopathological images, providing a solid foundation for future research on NENs.

NETRF requires grant recipients to share research resources, including datasets such as this one, with the research community. We strongly believe that sharing resources effectively will expedite the search for new treatments and a cure for neuroendocrine cancer.

Read the research article here.